Dexcom Beats EPS but Misses Revenue, Shares Slide 5.5% in After‑Hours Trade

Earnings Snapshot

- GAAP EPS: $0.51 vs. $0.47 consensus (beat by $0.04)

- Non‑GAAP EPS: $0.56 vs. $0.47 consensus (beat by $0.09)

- Revenue: $1.192 billion vs. $1.17 billion consensus (missed by $22 million, or 1.9%)

- YoY Revenue Growth: 15%

- Gross Margin: 62.9% (up from 56.9% a year ago)

- After‑Hours Price: $56.25, down 5.55% from the prior close of $59.55.

Why the Stock Fell

The market’s reaction was driven primarily by the revenue shortfall. While the EPS beat highlighted operational leverage, analysts had been betting on a stronger top‑line, especially after Dexcom’s aggressive rollout of the G7 15‑day CGM and international expansion. The $22 million miss, though modest in absolute terms, signaled that demand growth may be softening in the U.S., where revenue rose only 11% versus a 26% jump overseas.

Guidance and Outlook

Dexcom reaffirmed its FY 2026 revenue outlook of $5.16‑$5.25 billion (≈11‑13% growth) and lifted its non‑GAAP operating‑margin target to 23‑23.5% while keeping the non‑GAAP gross‑profit margin guidance at 63‑64%. CEO Jake Leach emphasized that the company “delivered strong revenue growth and margin performance… reflecting healthy demand for Dexcom CGM.” He also hinted at an upcoming Investor Day where the firm will detail its long‑term growth strategy.

Conference Call Highlights

Key takeaways from the Benzinga‑provided earnings‑call transcript:

- The G7 15‑day sensor is now available across all U.S. channels, and early adoption metrics are “on track” with prior launch phases.

- International markets, especially Europe and Asia‑Pacific, are delivering double‑digit growth, offsetting slower U.S. momentum.

- Dexcom introduced enhanced Smart Meal Logging on its Stelo platform, aiming to deepen engagement with type‑2‑diabetes patients not on insulin.

- Management reaffirmed confidence in cash flexibility, noting $2.42 billion in cash and marketable securities.

Analyst Reaction

Street‑level commentary from Benzinga and Seeking Alpha analysts noted that the revenue miss, albeit small, was “a red flag for U.S. market saturation.”

- Wedbush trimmed its 12‑month price target by 4% to $62, citing “the need for a clearer path to sustained U.S. growth.”

- Jefferies maintained a neutral stance but warned that “margin expansion alone may not offset top‑line weakness if competitive pressure intensifies.”

- Morgan Stanley upgraded the stock to “hold” from “underweight,” pointing to the robust margin profile and strong international tailwinds.

Sector Context

Dexcom’s slide mirrors a broader trend in the medical‑device/diabetes‑tech space, where investors are increasingly sensitive to revenue guidance. Peers such as Insulet and Abbott posted solid top‑line growth in the same earnings window, putting additional pressure on Dexcom to demonstrate comparable U.S. traction.

Outlook

The next catalyst will be Dexcom’s Investor Day slated for early May, where the company is expected to outline its roadmap for expanding CGM adoption among non‑insulin‑using type‑2 patients and to detail capacity‑building initiatives. Until then, the stock is likely to remain under pressure as analysts monitor the pace of international growth versus U.S. saturation.

---

All figures are from Dexcom’s Q1 2026 8‑K filing and consensus estimates compiled by market data providers.